New targeted pill shows promise for rare bile duct cancer in Real-World study
NCT ID NCT06607302
First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study is tracking 100 adults with a rare and aggressive bile duct cancer that has a specific IDH1 gene mutation. Participants will take the targeted drug ivosidenib, which was recently approved in Europe. Researchers will monitor how long the cancer stays under control, overall survival, and quality of life in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivosidenib (a targeted cancer pill)
- What this could lead to
- If successful, this study could confirm that ivosidenib is a safe and effective treatment option for people with this rare bile duct cancer, potentially improving survival and quality of life.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. The cancer is aggressive, and the drug may not work for everyone or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Caritas Krankenhaus Bad Mergentheim
RECRUITINGBad Mergentheim, Germany
-
DRK Kliniken Berlin, Klinik für Innere Medizin
RECRUITINGBerlin, Germany
-
Gemeinschaftspraxis Hämatologie - Onkologie
RECRUITINGDresden, Germany
-
Gemeinschaftspraxis für Internistische Onkologie und Hämatologie
RECRUITINGRheine, Germany
-
Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda
RECRUITINGBad Liebenwerda, Germany
-
Medizinisches Versorgungszentrum Mönchengladbach
RECRUITINGMönchengladbach, Germany
-
Onkologie Hannover
RECRUITINGHanover, Germany
-
Onkologie Hof
RECRUITINGHof, Germany
-
Onkologisches Versorgungszentrum Berlin MVZ
RECRUITINGBerlin, Germany
-
Onkologisches Zentrum Passau
RECRUITINGPassau, Germany
-
Onkozentrum Dresden
RECRUITINGDresden, Germany
-
RoMed Klinikum Rosenheim, Hämatologie und Onkologie
RECRUITINGRosenheim, Germany
-
TUM Klinikum Rechts der Isar, Klinik und Poliklinik für Innere Medizin II
RECRUITINGMünchen, Germany
-
Universitätsklinikum Augsburg, II. Medizinische Klinik
RECRUITINGAugsburg, Germany
-
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
RECRUITINGEssen, Germany
-
ze:roPRAXEN MVZ für Innere Medizin
RECRUITINGWeinheim, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Web tool aims to empower rare cancer patients in genomic choices